Our top pick for
Biomerica, Inc is a diagnostics & research business based in the US. Biomerica shares (BMRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biomerica employs 65 staff and has a trailing 12-month revenue of around USD$6.6 million.
|Latest market close||USD$6.37|
|52-week range||USD$2.05 - USD$12.75|
|50-day moving average||USD$6.32|
|200-day moving average||USD$7.1629|
|Wall St. target price||USD$11.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.26|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||19.51%|
|1 month (2020-12-16)||14.98%|
|3 months (2020-10-15)||-12.62%|
|6 months (2020-07-15)||-33.37%|
|1 year (2020-01-15)||125.09%|
|2 years (2019-01-15)||207.00%|
|3 years (2018-01-12)||28.69%|
|5 years (2016-01-15)||409.60%|
|Revenue TTM||USD$6.6 million|
|Gross profit TTM||USD$1.8 million|
|Return on assets TTM||-19.62%|
|Return on equity TTM||-42.98%|
|Market capitalisation||USD$58.4 million|
TTM: trailing 12 months
There are currently 769,454 Biomerica shares held short by investors – that's known as Biomerica's "short interest". This figure is 3.7% down from 799,263 last month.
There are a few different ways that this level of interest in shorting Biomerica shares can be evaluated.
Biomerica's "short interest ratio" (SIR) is the quantity of Biomerica shares currently shorted divided by the average quantity of Biomerica shares traded daily (recently around 87042.307692308). Biomerica's SIR currently stands at 8.84. In other words for every 100,000 Biomerica shares traded daily on the market, roughly 8840 shares are currently held short.
However Biomerica's short interest can also be evaluated against the total number of Biomerica shares, or, against the total number of tradable Biomerica shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biomerica's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Biomerica shares in existence, roughly 70 shares are currently held short) or 0.08% of the tradable shares (for every 100,000 tradable Biomerica shares, roughly 80 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Biomerica.
Find out more about how you can short Biomerica stock.
We're not expecting Biomerica to pay a dividend over the next 12 months.
Biomerica's shares were split on 7 April 2016.
Over the last 12 months, Biomerica's shares have ranged in value from as little as $2.05 up to $12.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomerica's is -0.4856. This would suggest that Biomerica's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biomerica has bucked the trend.
Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.